| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13121* | 2021 |
| DNAJC13 mutations in Parkinson disease C Vilariño-Güell, A Rajput, AJ Milnerwood, B Shah, C Szu-Tu, J Trinh, I Yu, ... Human molecular genetics 23 (7), 1794-1801, 2014 | 351 | 2014 |
| Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p. D620N LN Munsie, AJ Milnerwood, P Seibler, DA Beccano-Kelly, I Tatarnikov, ... Human molecular genetics 24 (6), 1691-1703, 2015 | 152 | 2015 |
| Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study E Esposito, P Mariani, L Ravani, C Contado, M Volta, S Bido, M Drechsler, ... European journal of pharmaceutics and biopharmaceutics 80 (2), 306-314, 2012 | 132 | 2012 |
| Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice DA Beccano-Kelly, N Kuhlmann, I Tatarnikov, M Volta, LN Munsie, ... Frontiers in cellular neuroscience 8, 301, 2014 | 129 | 2014 |
| LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory DA Beccano-Kelly, M Volta, LN Munsie, SA Paschall, I Tatarnikov, K Co, ... Human molecular genetics 24 (5), 1336-1349, 2015 | 105 | 2015 |
| A new hypothesis for Parkinson’s disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics J Obergasteiger, G Frapporti, PP Pramstaller, AA Hicks, M Volta Molecular neurodegeneration 13 (1), 40, 2018 | 87 | 2018 |
| Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice M Volta, DA Beccano-Kelly, SA Paschall, S Cataldi, SE MacIsaac, ... Elife 6, e28377, 2017 | 85 | 2017 |
| Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease M Volta, AJ Milnerwood, MJ Farrer The Lancet Neurology 14 (10), 1054-1064, 2015 | 74 | 2015 |
| LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis M Volta, H Melrose Biochemical Society Transactions 45 (1), 113-122, 2017 | 60 | 2017 |
| Memory and synaptic deficits in Hip14/DHHC17 knockout mice AJ Milnerwood, MP Parsons, FB Young, RR Singaraja, S Franciosi, ... Proceedings of the National Academy of Sciences 110 (50), 20296-20301, 2013 | 56 | 2013 |
| Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered … M Volta, S Cataldi, D Beccano-Kelly, L Munsie, I Tatarnikov, P Chou, ... Parkinsonism & Related Disorders 21 (10), 1156-1163, 2015 | 54 | 2015 |
| Behavioral deficits and striatal DA signaling in LRRK2 p. G2019S transgenic rats: a multimodal investigation including PET neuroimaging MD Walker, M Volta, S Cataldi, K Dinelle, D Beccano-Kelly, L Munsie, ... Journal of Parkinson's disease 4 (3), 483-498, 2014 | 44 | 2014 |
| Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions J Obergasteiger, G Frapporti, G Lamonaca, S Pizzi, A Picard, AA Lavdas, ... Cell death discovery 6 (1), 45, 2020 | 39 | 2020 |
| Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK‐21273 in comparison with SB‐612111 M Marti, F Mela, M Budri, M Volta, D Malfacini, S Molinari, NT Zaveri, ... British journal of pharmacology 168 (4), 863-879, 2013 | 39 | 2013 |
| Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6‐hydroxydopamine lesioned rats: new … OS Mabrouk, M Volta, M Marti, M Morari Journal of neurochemistry 107 (6), 1647-1659, 2008 | 33 | 2008 |
| Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson’s disease: a behavioral and neurochemical study in reserpinized mice M Volta, OS Mabrouk, S Bido, M Marti, M Morari Journal of neurochemistry 115 (6), 1543-1555, 2010 | 31 | 2010 |
| Cryopreservation of primary mouse neurons: the benefit of neurostore cryoprotective medium F Pischedda, C Montani, J Obergasteiger, G Frapporti, C Corti, ... Frontiers in Cellular Neuroscience 12, 81, 2018 | 29 | 2018 |
| Dopamine–nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons … M Volta, R Viaro, C Trapella, M Marti, M Morari Experimental neurology 228 (1), 126-137, 2011 | 28 | 2011 |
| Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1, 2, 3, 6 … M Volta, M Marti, J McDonald, S Molinari, V Camarda, M Pelà, C Trapella, ... Peptides 31 (6), 1194-1204, 2010 | 23 | 2010 |
